← Back to Search

Other

Brain Stimulation for Alzheimer's Disease

N/A

Waitlist Available

Led By Li-Huei Tsai, PhD

Research Sponsored by Massachusetts Institute of Technology

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Subject is between the ages of 50 - 100

Subject must have mild Alzheimer's disease with a Mini Mental State Exam (MMSE) score of 19 -26

Timeline

Screening 3 weeks

Treatment Varies

Follow Up immediately after the completion of the stimulation

Awards & highlights

Study Summary

This trial will test whether a non-invasive brain stimulation technique can remove toxic proteins and improve memory in people with mild Alzheimer's disease.

Who is the study for?

This trial is for individuals aged 50-100 with mild Alzheimer's Disease, having a Mini Mental State Exam score of 19-26. Participants must consent to the study; if unable, a legal representative can consent for them. Excluded are those without healthcare, on certain medications like NMDA antagonists or anti-seizure drugs, recent stroke survivors, pregnant women, and those with severe hearing or visual impairments.Check my eligibility

What is being tested?

The GENUS device is being tested in this trial. It uses light and sound stimulation aimed at improving brain functions in patients with mild Alzheimer's disease. The study will monitor brain waves before, during, and after using the device to evaluate safety and effectiveness.See study design

What are the potential side effects?

Since this is a non-invasive treatment involving light and sound stimulation designed to improve cognitive function in Alzheimer's patients, side effects may be minimal but are not detailed in the provided information.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 50 and 100 years old.

Select...

My Alzheimer's is mild, with an MMSE score between 19 and 26.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline and immediately after the completion of the stimulation

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline and immediately after the completion of the stimulation

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and immediately after the completion of the stimulation for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Feasibility of gamma frequency stimulation

Safety of gamma frequency stimulation

Tolerability of gamma frequency stimulation

Other outcome measures

Changes in working memory after gamma frequency stimulation

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: Exposure to active stimulation for 30 - 60 minExperimental Treatment1 Intervention

Subjects in this arm will receive 30 - 60 minutes of active stimulation

Group II: Exposure to control stimulation for 30 - 60 minPlacebo Group1 Intervention

Subjects in this arm will receive 30 - 60 minutes of control stimulation

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Massachusetts Institute of TechnologyLead Sponsor

97 Previous Clinical Trials

12,729,907 Total Patients Enrolled

Li-Huei Tsai, PhDPrincipal InvestigatorMassachusetts Institute of Technology

3 Previous Clinical Trials

115 Total Patients Enrolled

Edward S Boyden, PhDPrincipal InvestigatorMassachusetts Institute of Technology

1 Previous Clinical Trials

15 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does the age range for this trial encompass those under 25 years old?

"The target cohort for this medical research is individuals aged between 50 and 100 years old."

Answered by AI

Are any participants being accepted for this experiment at present?

"Clinicaltrials.gov provides evidence that this particular medical trial is not enrolling any more patients; it was initially posted on April 19th 2019 and the last update occurred September 13th 2021. Nevertheless, there are still 552 other trials actively recruiting individuals at the present moment."

Answered by AI

Do I possess the qualifications to join this medical research experiment?

"This Alzheimer's clinical trial has 80 vacancies for participants aged between 50 and 100 years old. To be accepted into the program, applicants must meet certain criteria such as having a mild form of the disease with an MMSE score ranging from 19 to 26, agreeing to sign informed consent documents (or having their legally authorized representative do so if they lack capacity)."

Answered by AI

Recent research and studies

NeuronJournal

Gamma Entrainment Binds Higher-order Brain Regions and Offers Neuroprotection

Adaikkan, Chinnakkaruppan, Steven J. Middleton, Asaf Marco, Ping-Chieh Pao, Hansruedi Mathys, David Nam-Woo Kim, Fan Gao, et al.. 2019. “Gamma Entrainment Binds Higher-order Brain Regions and Offers Neuroprotection”. Neuron. Elsevier BV. doi:10.1016/j.neuron.2019.04.011.

CellJournal

Multi-sensory Gamma Stimulation Ameliorates Alzheimer’s-associated Pathology and Improves Cognition

Martorell, Anthony J., Abigail L. Paulson, Ho-Jun Suk, Fatema Abdurrob, Gabrielle T. Drummond, Webster Guan, Jennie Z. Young, et al.. 2019. “Multi-sensory Gamma Stimulation Ameliorates Alzheimer’s-associated Pathology and Improves Cognition”. Cell. Elsevier BV. doi:10.1016/j.cell.2019.02.014.

NatureJournal

Gamma Frequency Entrainment Attenuates Amyloid Load and Modifies Microglia

Iaccarino, Hannah F., Annabelle C. Singer, Anthony J. Martorell, Andrii Rudenko, Fan Gao, Tyler Z. Gillingham, Hansruedi Mathys, et al.. 2016. “Gamma Frequency Entrainment Attenuates Amyloid Load and Modifies Microglia”. Nature. Springer Science and Business Media LLC. doi:10.1038/nature20587.

clinicaltrials.govStudy